CD19 Protein (AA 20-291) (His tag,FITC)
Quick Overview for CD19 Protein (AA 20-291) (His tag,FITC) (ABIN7274067)
Target
See all CD19 ProteinsProtein Type
Origin
Source
Purity
-
-
Protein Characteristics
- AA 20-291
-
Purification tag / Conjugate
- This CD19 protein is labelled with His tag,FITC.
-
Purpose
- FITC-Compatible Human CD19 Protein
-
Sequence
- Pro20-Lys291
-
Characteristics
- FITC-Compatible Human CD19 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Pro20-Lys291.
-
Sterility
- 0.22 μm filtered
-
Endotoxin Level
- Less than 1EU per μg by the LAL method.
-
-
Want other Options for this Protein ?
!Discover Our Predefined Custom Proteins and Custom Protein Services!Your project requires further customization? Contact us and discover our custom protein solutions
-
-
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Buffer
- Supplied as 0.22 μm filtered solution in PBS ( pH 7.4).
-
Storage
- -80 °C
-
Storage Comment
- Valid for 12 months from date of receipt when stored at -80°C., Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
-
Expiry Date
- 12 months
-
-
- CD19 (CD19 Molecule (CD19))
-
Alternative Name
- CD19
-
Background
- CD19 is a B-lineage-specific transmembrane glycoprotein, the expression of which is maintained on more than 95 % B-cell malignancies. This strict lineage restriction makes CD19 an ideal target for immune therapies using chimeric antigen receptors (CARs). T cells engineered to express a chimeric antigen receptor (CAR) against CD19 have recently been FDA approved for the treatment of relapsed or refractory large B-cell lymphoma. Despite the success and curative potential of CD19 CAR T cells, several reports describing disease relapse due to antigen loss are now emerging.
-
Molecular Weight
- 60.1 kDa. Due to glycosylation, the protein migrates to 68-72 kDa based on Tris-Bis PAGE result.
-
Pathways
- Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway
Target
-